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Abstract
Background: Asthma is one of the commonest chronic diseases in the UK. Acute exacerbations of asthma are
unpredictable, disruptive and frightening. They cause considerable morbidity and account for a large component of the
health service costs of asthma. The widespread use of an asthma self-management plan, designed to encourage disease
monitoring and timely intervention, can reduce exacerbations and is, therefore, recommended for all patients with
asthma. Unfortunately, the majority of patients are not provided with such a plan. There are a variety of reasons for this
but uncertainty about what to include in the plan when asthma control is deteriorating, but before the need for orally
administered corticosteroids, is a contributing factor.
The aim of this trial is to determine whether an asthma self-management plan, which includes a temporary quadrupling
of the dose of inhaled corticosteroid when asthma control starts to deteriorate, reduces asthma exacerbations requiring
orally administered corticosteroids or unscheduled health care consultation for asthma.
Methods: A multicentre, pragmatic, randomised trial in adults aged over 16 years with a clinical diagnosis of asthma,
treated with a licensed dose of inhaled corticosteroid and at least one exacerbation in the previous 12 months
requiring treatment with systemic corticosteroids. Participants will be randomised to either a self-management plan,
which includes a temporary (maximum of 14 days) fourfold increase in inhaled corticosteroid or the same plan without
an increase in inhaled corticosteroid. Participants will be followed up at 6 and 12 months and will attend the clinic for
an additional visit if their asthma control deteriorates. The primary outcome is time to first asthma exacerbation,
defined as the need for systemic corticosteroids and/or unscheduled health care consultation for asthma. The
estimated sample size is 1800 participants.
Discussion: The FAST trial is an independent study that has been prioritised and commissioned by the National
Institute for Health Research (NIHR) in the United Kingdom. It will provide high-quality evidence to inform clinical
decision-making on the role of an asthma self-management plan, which includes a temporary fourfold increase of
inhaled corticosteroid, when asthma control starts to deteriorate.
The first participant was randomised on 17th May 2013 and recruitment will close on 31 January 2016 with the last
(Continued on next page)
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patient last visit taking place in January 2017.
Trial registration: ISRCTN: 15441965, registered on 25 April 2013.
Keywords: Asthma, Exacerbation, Self-management plan, Inhaled corticosteroids, Oral corticosteroids Randomised
controlled trial, Fourfold, Protocol, Primary care
Background
Asthma is one of the commonest chronic diseases in the
UK. Acute exacerbations or attacks of asthma cause consid-
erable morbidity and account for a large component of the
costs of asthma.
Self-management plans have been shown to reduce ex-
acerbations requiring orally administered corticosteroids
and emergency health care utilisation [1]. Unfortunately,
the majority of patients with asthma are not provided
with a written self-management plan [2] and only 23 %
of patients dying from asthma in the UK were known to
have been given a written self-management plan [3]. Al-
though there are a variety of reasons for this, confusion
about what to include in the plan when asthma control
is deteriorating, but before the need for orally adminis-
tered corticosteroids, is one important limiting factor.
Two large, randomised, double-blind, placebo-controlled
clinical trials have found no benefit from doubling the dose
of a patient’s usual inhaled corticosteroid [4] or doubling
the dose of inhaled budesonide [5] when asthma control
starts to deteriorate. However, other studies have suggested
that a fourfold increase [6], a fivefold increase [7] or 2 mg
inhaled fluticasone propionate added to current therapy [8]
can prevent the progression of an exacerbation.
The aim of this trial is to determine whether an asthma
self-management plan, which includes a temporary quad-
rupling of the dose of inhaled corticosteroid when asthma
control starts to deteriorate, reduces asthma exacerbations
requiring orally administered corticosteroids or unsched-
uled health care consultation for asthma.
Objectives
Overall we will determine the clinical and cost-effectiveness
of an asthma self-management plan, which includes a tem-
porary quadrupling of the dose of inhaled corticosteroid
when asthma control starts to deteriorate, at preventing an
asthma exacerbation which is defined as: the need for sys-
temic corticosteroids and/or unscheduled health care con-
sultation for asthma (i.e. reaching zone 3 or 4 of the
Asthma UK self-management plan).
The primary objective it to determine whether the pro-
posed asthma self-management plan reduces asthma exac-
erbations requiring orally administered corticosteroids or
unscheduled health care consultation for asthma.
The secondary objectives are to (1) determine whether
the proposed asthma self-management plan reduces the
deterioration in asthma control, and (2) to determine if
the proposed asthma self-management plan is cost-
effective to the NHS and society overall.
Methods/design
This is a multicentre, pragmatic, randomised trial com-
paring the clinical and cost-effectiveness of a self-
management plan, which includes a temporary fourfold
increase in inhaled corticosteroid with the same plan
without an increase in inhaled corticosteroid.
Flow of participants through the trial is summarised in
Fig. 1.
Participants, interventions and outcomes
Setting
Potential participants will be recruited from both pri-
mary and secondary care across England and Scotland
and through local advertising (self-referral). We envisage
that the majority of participants (approximately 80 %)
will be recruited within primary care.
For primary care we plan to recruit from general prac-
titioner (GP) practices across England and Scotland in
conjunction with the Primary Care Research Network
(PCRN/SPCRN). The model of recruitment will depend
on the models of delivery within the differing PCRN
areas. The lead PCRN based within the chief investiga-
tor’s region (East Midlands and South Yorkshire PCRN)
will be responsible for facilitating the set-up of the study
within primary care and will liaise with the relevant local
PCRNs based within the collaborating centres’ region.
Local PCRNs will liaise directly with GP practices who
will act as Participant Identification Centres (PICs).
At secondary care sites participants will be identified
from patients attending respiratory outpatient appoint-
ments at the individual NHS Trust recruiting centres. The
first contact will be made by the patient’s clinician or a
member of their immediate care team within the clinic.
They will be given a brief overview of the study and a Par-
ticipant Information Sheet (PIS) will be provided. Sites were
chosen on the basis of a proven track record of recruiting
into previous asthma trials.
Eligibility
Inclusion criteria
 Male or female patients aged 16 years and over
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 Clinician-diagnosed asthma treated with a licensed
dose of inhaled corticosteroid (i.e. steps 2 to 4 of the
British Thoracic Society/Scottish Intercollegiate
Guidelines Network (BTS/SIGN) guidelines)
 One or more asthma exacerbation in the last
12 months requiring treatment with systemic
corticosteroids
Exclusion criteria
 A history more in keeping with smoking-related
chronic obstructive pulmonary disease (COPD)
(smoked more than 20 pack years, without evidence
of significant reversibility and an absence of
eosinophilia)
 On maintenance orally administered corticosteroids
(i.e. step 5 of the BTS/SIGN guidelines)
 Using a combination inhaler for both maintenance
and relief treatment
 Experienced an asthma exacerbation within 4 weeks
of randomisation
 Pregnant women, lactating women or women who
are planning to become pregnant
Interventions
Participants will be randomised equally to one of two
asthma self-management plans developed from the Asthma
UK plan in use at the time (Appendix 1). Zones 1, 3 and 4
are identical and zone 2 includes the current area of uncer-
tainty and the research question under investigation
(Appendix 2).
At randomisation, participants will be provided with in-
structions on how to follow their allocated asthma self-
management plan and given guidance on how to complete
the Asthma Diary Card for 14 days when their asthma
deteriorates.
On reaching zone 2 of the plan the ‘modified group’ will
be advised to increase their bronchodilators and quadruple
their inhaled corticosteroid dose for 7 to 14 days (Appen-
dix 3 and 4) and the ‘usual care group’ will be advised to in-
crease their bronchodilator medication only.
Assessment of adherence with the two self-
management plans will include a review of the Asthma
Diary Card and specific questions about whether, and
how, participants changed their inhaled treatment since
activating zone 2 of the self-management plan. Adher-
ence will be classified as:
 In the modified (quadrupling) group:
∘ poor – no or minimal change in medication
∘ moderate – change but not as fourfold or instructed
∘ good – fourfold change and followed
instructions
 In the usual care (no change) group:
∘ poor – fourfold increase in maintenance dose
∘ moderate – increase in maintenance dose but
less than fourfold
Fig. 1 Timetable of study assessments
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∘ good – no change in inhaled corticosteroid dose
We will also capture whether participants who have
had a period of poor adherence simply restarted their in-
haled corticosteroid on activation of zone 2.
Outcomes
The primary outcome is ‘time to first asthma exacer-
bation’, defined as: the need for systemic corticoste-
roids and/or unscheduled health care consultation for
asthma (i.e. reaching zone 3 or 4 of the Asthma UK
self-management plan).
Secondary outcomes include the use of systemic
corticosteroids and unscheduled health care consulta-
tions for an acute exacerbation of asthma:.total
number of courses of systemic corticosteroids, total
number of unscheduled health care consultations,
time to participants requiring systemic corticosteroids
and time to unscheduled health care consultation for
an acute exacerbation of asthma, cumulative dose of
inhaled and systemic corticosteroids used in the
12 months after randomisation, area under the morn-
ing peak flow curve over 2 weeks after activating
stage 2 of the self-management plan and the Juniper
Mini Asthma Control Questionnaire (MiniAQLQ) [9].
The cost and resource audits of both trial arms will
be reported as incremental cost per asthma exacerba-
tion prevented and cost per quality-adjusted life year
(QALY) gained.
Participant timeline
The first patient was randomised on 17 May 2013 and
recruitment will close on 31 January 2016 with the last
patient’s last visit in January 2017.
Follow-up is at 6 months and at 12 months, either by
clinic visit or by telephone. Participants are enrolled into
the study for a total of 12 months. Information is being
collected on orally administered corticosteroid use,
unscheduled health care consultations, adverse events,
EQ-5D-3 L and Service Use Questionnaire (SUQ) data.
If asthma control deteriorates and zone 2 of the asthma
plan is activated, an additional post-activation visit is re-
quired after the 14-day Asthma Diary Card has been
completed. Adherence rating to the allocated asthma
self-management plan (via research nurse review of
completed Asthma Diary Card), exacerbation history
and MiniAQLQ [9] data are also being collected at this
visit Fig. 1.
A monthly text message reminder for follow-up visits
is sent to the participants if they have a mobile phone
and consent to receive this.
Details of the data collection schedule are summarised
in Fig. 1.
Sample size
A reduction of one third in the number of people requir-
ing treatment with orally administered corticosteroids
was considered an important treatment effect from a
group of local general practitioners, asthma nurses and
asthma experts.
With 1000 participants per group, a log-rank test
(at the two sided 5 % significance level) will have at
least 90 % power to detect a difference of 30 %, as-
suming an exacerbation rate of 13 % in the control
group. A 13 % exacerbation rate requiring systemic
corticosteroids is the lowest level seen in the control
group of previous studies of this type ([10, 11, 6])
and so provides us with a conservative estimate.
We initially proposed to recruit 2300 patients to allow
for participants lost to follow-up, although we plan to
obtain as much information about participants who have
withdrawn as possible using computerised records.
The power calculation was revised in March 2015 in
consultation with the NIHR Health Technology Assess-
ment. The overall event rate in the first 226 participants
recruited was shown to be higher around 20 % in those
reaching the 12-month follow-up, and therefore the
power calculation was re-calculated. Assuming a base-
line exacerbation rate in the control group of 17 % and
90 % power, and still estimating a one third reduction in
the four –fold increase group, then a sample size of
1542 is needed for analyses. Allowing for 20 % of partici-
pants being lost to follow up, we aim to recruit between
1774 and 1850 patients. Recruitment will close on 31st
January 2016.
Due to the interim event rate for the primary out-
come being higher than estimated the power calcula-
tion was revised. With a baseline exacerbation rate in
the control of 17 % and 90 % power and still estimat-
ing a one-third reduction in the fourfold increase
group, the sample size was revised to between 1750
and 1850 participants.
Recruitment
Potential participants are being recruited from both pri-
mary and secondary care in England and Scotland, with
an estimated split of about 80:20, respectively.
Primary care recruitment is in general practices across
England and Scotland in conjunction with Primary Care
Research Networks (subsequently local Clinical Research
Networks, CRN/SCRN), with practices either acting as
Participant Identification Centres (PICs) or Research Ini-
tiative Sites (RIS). Participants are being identified by a
database search and invitation letter and by opportunis-
tic recruitment in RISs.
Secondary care recruitment is from respiratory outpatient
clinics and via specific research volunteer databases.
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Follow-up
Follow-up is at 6 months and at 12 months, either by
clinic visit or by telephone. Information is being col-
lected on orally administered corticosteroid use, un-
scheduled health care consultations, adverse events, the
EuroQol five dimensions, three levels questionnaire
(EQ-5D-3 L) and Service Use Questionnaire (SUQ)
data. If asthma control deteriorates and zone 2 of the
asthma plan is activated, an additional post-activation
visit is required after the 14-day Asthma Diary Card
has been completed. Adherence rating to the allocated
asthma self-management plan (via research nurse re-
view of completed Asthma Diary Card), exacerbation
history and MiniAQLQ [9] data are also being collected
at this visit.
A monthly text message reminder for follow-up visits
is sent to the participants if they have a mobile phone
and consent to receive this.
Participant withdrawal and stopping criteria
For individual participants, discontinuation of the
treatment plan will be decided on an individual basis
that will include, but not be limited to, people who
have more than six asthma exacerbations in the 12-
month trial period.
Adherence with the self-management plans will be
reviewed at 12 months (and at 18 months if insufficient
data is available). If the self-reported adherence is reli-
able, the futility analysis will be based on the entire study
population. The Trial Steering Committee (TSC) will de-
termine whether the overall adherence with the self-
management plans makes the study futile and, therefore,
should be stopped.
Assignment of interventions
Randomisation and blinding
The randomisation schedule is based on a computer-
generated pseudo-random code using random permuted
blocks of randomly varying size, created by the Notting-
ham Clinical Trials Unit (Nottingham CTU) in accord-
ance with their standard operating procedure (SOP) and
held on a secure University of Nottingham server.
Randomisation is stratified by recruiting site (regional
centre), smoking status (yes/no) and maintenance of in-
haled corticosteroid dose (Appendix 5).
Investigators and research nurses access the random-
isation website by means of a remote, Internet-based
randomisation system developed and maintained by the
Nottingham CTU. The sequence of treatment alloca-
tions will be concealed until interventions have all been
assigned and recruitment, data collection and all other
trial-related assessments are complete.
This is an open-label clinical trial, so the participant and
the study team will be aware of the self-management plan
allocation. The chief investigator and trial statisticians are
blinded to participant treatment arms throughout the
study. Participants will be enrolled and randomised by a
member of the site study team.
Data collection, management and analysis
Data management
Clinic data are entered directly into a web-based trial
database at the investigator sites by site users with
unique login details. Patient questionnaires and Asthma
Diary Cards completed at clinic visits are entered by the
site nurses directly into the trial database.
Data quality is ensured by database validation checks
which include missing data, out of range values,
illogical entries and invalid responses. Data entered by
sites into the trial database are subject to review by
coordinating centre staff, and data queries are raised as
necessary.
Detailed data management processes and procedures
are documented in the FAST Data Management Plan.
Statistical methods
A detailed statistical analysis plan has been agreed
with the TSC. In summary, baseline characteristics
will be described for both treatment groups. For the
primary outcome variables, a log-rank test on Kaplan-
Meier survival graphs for time to asthma exacerbation
will be calculated. Multivariate analyses will also be
investigated, using Cox regression to adjust for the ef-
fect of any potential differences between the groups
at baseline. All analysis will be done as intention-to-
treat. Subgroup analyses for smoking status at trial
entry and high/low inhaled corticosteroid use at trial
entry will also be performed.
Monitoring
Data monitoring
Integrity of trial conduct is overseen by the TSC, which
meets at least once a year and provides overall supervi-
sion of the trial on behalf of the trial sponsor (University
of Nottingham).
The Trial Management Group (TMG) meets more fre-
quently and is responsible for the day-to-day manage-
ment of the trial. Members of the TMG report to the
TSC at their annual meetings.
The Data Monitoring Committee (DMC), meets at
least once a year and provides independent oversight of
trial data. The DMC report to the TSC.
The chief investigator has overall responsibility for the
study and is custodian of the data.
Interim analyses
There are no planned interim between-group analyses.
However, progress with recruitment and retention is
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monitored monthly by the TMG. If progress is below
target, strategies will be implemented to improve pro-
gress in discussion with the TSC.
Assessment of harm
Adverse events are only reported during the 14 days
following activation of zone 2 of the self-management
plan and are limited to oral candidiasis and dysphonia
as the adverse effects of inhaled corticosteroids are
well-known.
Serious adverse events (SAEs) are only reported during
the 14-day active treatment period, i.e. during activation
of zone 2 of the self-management plan. Additionally any
SAE that meets the criteria of a diagnosis of pneumonia
is also recorded and reported up to 1 month after the
14-day activation period.
Ethics and dissemination
Research ethics approval
Ethics approval was granted by NHS Health Research
Authority, North West – Greater Manchester South Re-
search Ethics Committee and the respective National
Health Service (NHS) Research and Development (R&D)
departments for participating sites. The trial is being
conducted in accordance with the ethical principles that
have their origin in the Declaration of Helsinki, 1996;
the principles of Good Clinical Practice and the Depart-
ment of Health Research Governance Framework for
Health and Social care, 2005.
Protocol amendments
The methods described in this protocol reflect the current
protocol (version 6.0 dated 5 November 2015). A sum-
mary of protocol amendments are summarised (Table 1).
All amendments to the protocol and associated paper-
work have been approved by the trial sponsor, the
Research Ethics Committee, local R&D departments and
the trial funder prior to implementation.
Consent
Written informed consent is obtained from all partici-
pants, who then provide demographic data on smoking
history and baseline inhaled corticosteroid medication.
Baseline peak expiratory flow (PEF), the MiniAQLQ [9]
and the EQ-5D-3 L [www.euroqol.org] questionnaire
scores are recorded and all data captured via an elec-
tronic data capture system.
No trial-specific procedures are conducted before in-
formed consent has been obtained, and participants are
reminded that they may withdraw from the trial at any
time without it affecting the quality of their future care.
Participants will be made aware (via the Participant Infor-
mation Sheet and Informed Consent Form) that should
they withdraw the data collected to date cannot be erased
and may still be used in the final project analysis.
Confidentiality
Individual participant medical information obtained as a
result of this study is confidential. Participant confidential-
ity will be ensured using identification code numbers
to correspond to treatment data in the computer files.
Patient-identifiable information is not stored by the
NCTU or sponsor.
Medical information may be given to the participant’s
medical team and all appropriate medical personnel re-
sponsible for the participant’s welfare.
Access to data
Data generated as a result of this trial will be available for
inspection on request by the participating physicians, the
University of Nottingham representatives, the Research
Table 1 Summary of protocol amendments that impacted on trial design
Protocol Date Summary of protocol changes
V 2.0 5 Aug
2013
• Minor wording added to the protocol to clarify that potential participants can be recruited from clinic appointments in
primary care
V 3.0 23 Oct
2013
• Table 3 – How to achieve a quadrupling dose for participants on a combination inhaler
• Clarification of the dose strength for Symbicort
• Clarification of inhaler type
• The addition of a new dose of Fostair and QVAR
• Clarification of a typographic error
V 4.0 3 Feb
2014
• Clarification of serious adverse event reporting timeframe
V 5.0 14 Oct
2014
• Use of the current approved advert to be placed on public notice boards, universities and on websites and social media
• Use of DocMail in GP practices
• Telephone consultation at 6 and 12 months if patient has not had an exacerbation
V 6.0 5 Nov
2015
• Additional wording to the sample size justification section of the protocol, reduction of sample size from 2300 to between
1774 and 1850, removal of paragraph and references pertaining to electronic dose counters (Smart-inhalers) and other minor
typographic clarifications
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Ethics Committee, local R&D departments and the regula-
tory authorities.
Requests for access to the original anonymised dataset
should be made to the chief investigator.
Post-trial care
After completing the study participants will continue to re-
ceive their standard asthma care through the NHS in accord-
ance with local practice. A summary of the trial results will
be provided to parents if they have given consent for this.
Dissemination policy
Results will be reported in full through the National In-
stitute for Health Research Journal series (open access),
as well as through peer-reviewed journals, patient news-
letters and websites.
The final report will follow the Consolidated Standards
of Reporting Trials (CONSORT) 2010 guideline as well
as its extension to pragmatic trials.
Patient and Public Involvement
Patients and members of the public have been actively
involved in the design and conduct of the FAST trial
throughout.
Full details of the extent of Patient and Public Involve-
ment, and the impact that this has had on delivery of
the trial, will be reported separately.
Trial status
The FAST trial is ongoing. The first participant was ran-
domised on 17 May 2013 and recruitment will close on 31
January 2016 with the last patient’s last visit taking place
on January 2017. Data collection, analysis and write-up
should be completed by the end of 2017.
Appendix 1
Fig. 2 Asthma UK self-management plan
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Appendix 2
Appendix 3
Appendix 4
Table 2 Zone 2 of the asthma self-management plan
Active group Control group
Zone 2 Zone 2
Your asthma is getting worse if
you have one or more of the
following:
• You need your reliever inhaler
more than twice a week
• You had difficulty sleeping
because of your asthma
• You have seasonal symptoms
(e.g. hay fever, cold)
• Your peak flow is around ___ or
lower
Your asthma is getting worse if
you have one or more of the
following:
• You need your reliever inhaler
more than twice a week
• You had difficulty sleeping
because of your asthma
• You have seasonal symptoms
(e.g. hay fever, cold)
• Your peak flow is around ___ or
lower
Action Action
Use your reliever inhaler to relieve
your symptoms and increase your
preventer medication as described
below
(individualised instructions on how
to achieve a fourfold increase)
Once your symptoms or peak flow
have returned to normal or after a
maximum of 14 days return to
your normal treatment
If your symptoms get worse follow
zone 3 instructions
Use your reliever inhaler to relieve
your symptoms and continue your
preventer medication at your
normal dose
Once your symptoms or peak flow
have returned to normal or after a
maximum of 14 days return to
your normal treatment
If your symptoms get worse follow
zone 3 instructions
Start to record your morning peak
flow, symptoms and medication in
the study diary
Start to record your morning peak
flow, symptoms and medication in
the study diary
Phone your research nurse to
arrange a study visit
Phone your research nurse to
arrange a study visit
Table 3 How to achieve a quadrupling dose for participants on an
inhaled corticosteroid-only inhaler (BDP,FP, budesonide, ciclesonide)
Current number of puffs Puffs to achieve quadrupled dose
1 od 4 od
2 od 8 od
1 bd 4 bd
2 bd 8 bd
bd twice daily, BDP beclomethasone dipropionate, FP fluticasone propionate,
od once daily
Table 4 How to achieve a quadrupling dose for participants on
a combination inhaler
Current treatment Additional treatment options
Option 1 Option 2
Seretide MDI 50/25 2 puffs bd FP 50, 6 puffs bd FP 125,
3 puffs bd
Seretide MDI 125/25, 2 puffs bd FP 125, 6 puffs bd FP 250, 3
puffs bd
Seretide MDI 250/25, 2 puffs bd FP 250, 6 puffs bd N/A
Seretide Accuhaler 100/50 1 puff bd FP Disk 100,
3 puffs bd
N/A
Seretide Accuhaler 250/50 1 puff bd FP Disk 250,
3 puffs bd
N/A
Seretide Accuhaler 500/50 1 puff bd FP Diskhaler 500,
3 puffs bd
N/A
Symbicort Turbo 100/6 1 puff bd Bud Turbo 100,
3 puffs bd
N/A
Symbicort Turbo 100/6 2 puffs bd Bud Turbo 100,
6 puffs bd
Bud Turbo 200,
3 puffs bd
Symbicort Turbo 200/6 1 puff bd Bud Turbo 200,
3 puffs bd
N/A
Symbicort Turbo 200/6 2 puffs bd Bud Turbo 200,
6 puffs bd
Bud Turbo 400,
3 puffs bd
Symbicort Turbo 200/6 4 puffs bd Bud Turbo 400,
6 puffs bd
N/A
Symbicort Turbo 400/12 1 puff bd Bud Turbo 400,
3 puffs bd
N/A
Symbicort Turbo 400/12 2 puffs bd Bud Turbo 400,
6 puffs bd
N/A
Fostair MDI 100/6, 1 puff bd QVAR MDI 100,
3 puffs bd
N/A
Fostair MDI 100/6, 2 puffs bd QVAR MDI 100,
6 puffs bd
N/A
Flutiform MDI 50/5, 2 puff bd FP MDI 50,
6 puffs bd
N/A
Flutiform MDI 125/5, 2 puffs bd FP MDI 125,
6 puffs bd
FP MDI 250,
3 puffs bd
Flutiform MDI 250/10, 2 puffs bd FP MDI 250,
6 puffs bd
N/A
bd twice daily, Bud budesonide, FP fluticasone dipropionate, MDI
metered-dose inhaler
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Appendix 5
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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Table 5 High and low doses for stratification purposes
Corticosteroid Device and
formulation
Low dose
mcg/day
High dose
mcg/day
BDP Non-proprietary 100–1000 >1000–2000
BDP Clenil MDI 100–1000 >1000–2000
BDP QVAR MDI 50–500 >500–800
Budesonide MDI 100–1000 >1000–1600
Budesonide Turbuhaler 100–800 >800–1600
Fluticasone propionate MDI/Accuhaler 50–500 >500–2000
Ciclesonide MDI 80–320
Seretide MDI/Accuhaler 50–500 >500–1000
Symbicort Turbuhaler 100–800 >800–1600
Fostair MDI 400
Flutiform MDI 50–500 >500–1000
BPD beclomethasone dipropionate, MDI metered-dose inhaler
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